Vertex, Entrada to Collaborate on Therapeutics for Myotonic Dystrophy

  Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties -

- Global collaboration includes ENTR-701, Entrada’s EEV-investigational candidate for the treatment of DM1 -

https://finance.yahoo.com/news/vertex-entrada-therapeutics-establish-collaboration-120000140.html